Niclosamide

The global demand for prevention and control of helminth infections continues to rise. As a classic molluscicidal and anti-helminth drug, niclosamide is a salicylamide derivative. It inhibits the oxidative phosphorylation process of mitochondria in parasite cells and blocks energy metabolic pathways, so that it can quickly kill oncomelania snails and Schistosoma cercariae, and also has significant killing activity against a variety of parasites such as tapeworms and paramphistomes in cattle and sheep. Clinically, it is used not only for the prevention and control of schistosomiasis transmission in epidemic areas, but also for the treatment of human taeniasis and parasitic infections in livestock and poultry such as cattle and sheep, making it one of the core drugs in the public health field and the animal husbandry and breeding industry.

Available public data show that the global market size of niclosamide is approximately USD 120 million, with a stable compound annual growth rate of 3.7%. Its market pattern is dominated by generic drugs, with downstream demand concentrated in public procurement in epidemic areas and the veterinary drug field. Domestic manufacturers in China account for nearly 62% of the global production capacity supply, making China a major exporter of niclosamide. In the centralized procurement of public medical institutions, the winning bid price of niclosamide preparations is about 48% lower than that of the originator drug, which further promotes the accessibility of grassroots medication.

The originator company of niclosamide is Bayer, with the original brand name "Mie Luo Ling". The core compound patent expired as early as 1960, and there are currently no core patent restrictions. The main dosage forms of the originator product include 0.5g tablets, liniments and suspensions for oncomelania snail killing. The originator tablets have been included in the FDA Reference Listed Drug Catalog, and no originator preparations have been imported into China. According to the domestic API registration platform, there are currently 11 enterprises that have obtained approval for registration of niclosamide APIs (status A), among which 7 also hold veterinary API approval numbers; domestic preparations such as niclosamide tablets and niclosamide ointment have been approved for marketing. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for niclosamide, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can fully support the experimental needs at different stages such as API R&D, quality research and consistency evaluation.